Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden
(2022) In Acta Ophthalmologica 100(4).- Abstract
Purpose: To analyse and compare the number and interval of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), as well as the visual development in patients followed up for one to three years in clinical practice and during different index periods. Methods: This observational study included treatment-naïve eyes with nAMD from the Swedish Macula Register that started treatment between 2007 and 2017, stratified by different index periods (2007–2010, 2011–2013, 2014–2015 and 2016–2017) and by follow-up cohorts for each index period of one, two or three years (cohorts 1–3). Their intravitreal anti-VEGF treatment was assessed by number of injections, injection intervals,... (More)
Purpose: To analyse and compare the number and interval of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), as well as the visual development in patients followed up for one to three years in clinical practice and during different index periods. Methods: This observational study included treatment-naïve eyes with nAMD from the Swedish Macula Register that started treatment between 2007 and 2017, stratified by different index periods (2007–2010, 2011–2013, 2014–2015 and 2016–2017) and by follow-up cohorts for each index period of one, two or three years (cohorts 1–3). Their intravitreal anti-VEGF treatment was assessed by number of injections, injection intervals, visual acuity (VA) and near VA change. Results: From the earliest index period 2007–2010 to the latest 2016–2017, the number of injections increased for the comparable follow-up time; 6.2 ± 1.4 versus 8.3 ± 2.0 injections after 1 year of treatment, 4.8 ± 1.6 versus 6.7 ± 2.4 during year 2. The last injection interval was 73 ± 34 days after 1, 71 ± 33 after 2 and 67 ± 32 after 3 years of follow-up for the index period 2014–2015. For the same period, the percentage of eyes with at least two consecutive 12–16 weeks of injection interval over 1-, 2- and 3-year follow-up increased from 5.2%, 15.0%, to 17.5% respectively. Baseline VA for eyes indexed 2016–2017 increased and presented with 62.1 ± 13.4 letters compared with 57.7 ± 13.5 letters in 2007–2010; p < 0.0001. Conclusions: From the earliest to the latest index periods, the number of injections increased for the comparable follow-up time. Accordingly, baseline VA and near VA and their outcomes improved continuously.
(Less)
- author
- Schroeder, Marion LU ; Westborg, Inger ; Fluur, Caroline ; Olsen, Rasmus and Lövestam-Adrian, Monica LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- anti-vascular endothelial growth factor, neovascular age-related macular degeneration, real world, Swedish macula register
- in
- Acta Ophthalmologica
- volume
- 100
- issue
- 4
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:34543528
- scopus:85115191740
- ISSN
- 1755-375X
- DOI
- 10.1111/aos.15025
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation
- id
- f8793e7c-9cb0-457d-8dfa-9b7d874a75cb
- date added to LUP
- 2021-10-12 15:25:13
- date last changed
- 2024-12-29 14:28:20
@article{f8793e7c-9cb0-457d-8dfa-9b7d874a75cb,
abstract = {{<p>Purpose: To analyse and compare the number and interval of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), as well as the visual development in patients followed up for one to three years in clinical practice and during different index periods. Methods: This observational study included treatment-naïve eyes with nAMD from the Swedish Macula Register that started treatment between 2007 and 2017, stratified by different index periods (2007–2010, 2011–2013, 2014–2015 and 2016–2017) and by follow-up cohorts for each index period of one, two or three years (cohorts 1–3). Their intravitreal anti-VEGF treatment was assessed by number of injections, injection intervals, visual acuity (VA) and near VA change. Results: From the earliest index period 2007–2010 to the latest 2016–2017, the number of injections increased for the comparable follow-up time; 6.2 ± 1.4 versus 8.3 ± 2.0 injections after 1 year of treatment, 4.8 ± 1.6 versus 6.7 ± 2.4 during year 2. The last injection interval was 73 ± 34 days after 1, 71 ± 33 after 2 and 67 ± 32 after 3 years of follow-up for the index period 2014–2015. For the same period, the percentage of eyes with at least two consecutive 12–16 weeks of injection interval over 1-, 2- and 3-year follow-up increased from 5.2%, 15.0%, to 17.5% respectively. Baseline VA for eyes indexed 2016–2017 increased and presented with 62.1 ± 13.4 letters compared with 57.7 ± 13.5 letters in 2007–2010; p < 0.0001. Conclusions: From the earliest to the latest index periods, the number of injections increased for the comparable follow-up time. Accordingly, baseline VA and near VA and their outcomes improved continuously.</p>}},
author = {{Schroeder, Marion and Westborg, Inger and Fluur, Caroline and Olsen, Rasmus and Lövestam-Adrian, Monica}},
issn = {{1755-375X}},
keywords = {{anti-vascular endothelial growth factor; neovascular age-related macular degeneration; real world; Swedish macula register}},
language = {{eng}},
number = {{4}},
publisher = {{Wiley-Blackwell}},
series = {{Acta Ophthalmologica}},
title = {{Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden}},
url = {{http://dx.doi.org/10.1111/aos.15025}},
doi = {{10.1111/aos.15025}},
volume = {{100}},
year = {{2022}},
}